Vivien Puspitasari, Anyeliria Sutanto, Aristo Rinaldi Pangestu
  MNJ, pp. 97-104  


Multiple sclerosis is a chronic autoimmune disease that attacks myelin in the central nervous system. About 2.5 million people worldwide have been diagnosed with multiple sclerosis. Its clinical presentation could vary according to the location of the lesion. Interferon beta is the most commonly used as immunomodulation therapy. However, its effectiveness for long-term use is still questionable. We report a case of 24-year-old woman with complaints of ataxia and limb weakness which were diagnosed as multiple sclerosis relapsing remitting (MSRR) and treated with interferon beta 1a for five years. During routine interferon beta 1a treatment three times a week, patient has still experienced four episodes of relapse in spite of good compliance. Hence, the rare presence of neutralizing antibodies was suspected. It commonly occurs after a year of interferon therapy, which is consistent with the patient’s treatment history. Further biomarker testing of drug-specific antibodies might be valuable to find out the possibility of interferon resistance


Autoimmune, demyelinitation, interferon beta, multiple sclerosis

Full Text:



Langer-Gould A, Brara SM, Beaber BE, Zhang JL. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology; 2013. 80(19);1734-9.

DOI: 10.1212/WNL.0b013e3182918cc2

Cheong WL, Mohan D, Warren N, Reidpath DD. Multiple sclerosis in the asia pacific region: A systematic review of a neglected neurological disease.

Front Neurol; 2018. 9(432);1-9.

DOI: 10.3389/fneur.2018.00432

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Fillippi M, et al. Diagnostic criteria for multiple sclerosis; 2010 revisions to the McDonald criteria. Ann Neural. 2011. 69(2);292-302.

DOI: 10.1002/ana.22366

Ropper AH, Brown RH. Adam and Victor's Principle of Neurology, 10th ed. China: McGraw-Hill; 2014

Boz C, Oger J, Gibbs E, Grossberg SE. Reduced effectiveness of long-term interferon –beta treatment on relapses in neutralizing antibosy-positive multiple sclerosis patients: a Canadian sclerosis clinic-based study. Mult Scler; 2007. 13(9); 1127-37. DOI: 10.1177/1352458507080468

Tomassini V, Paolillo A, Russo P, Giugni E, Prosperini L, Gasperini C, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol; 2006. 253(3);287-93.

DOI: 10.1007/s00415-005-0979-5

Sorensen PS. Neutralizing antibodies againts interferon-beta. Therapeutic Advances in Neurological Disorders; 2008. 1(2);124-41.

DOI: 10.1177/1756285608095144

Browne P, Chandraratna D, Thompson AJ. Atlas of multiple sclerosis 2013: A growing global problem with widespread inequity. Neurology; 2014. 83(11);1022-1024.

DOI: 10.1212/WNL.0000000000000768

Wilkins A. Cerebellar dysfunction in multiple sclerosis. Front Neurol; 2017. 8(312);1-6.

DOI: 10.3389/fneur.2017.00312

Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemar SF, Lassmann H, et al. lnflammatory cortical demyelination in early multiple sclerosis. N Eng J Med; 2011. 365;2188-97.

DOI: 10.1056/NEJMoa1100648

Moroso A, Ruet A, Deloire M, Lamargue-Hamel D, Cubizolle S, Charré- Morin J, et al. Cerebellar assessment in early multiple sclerosis. Cerebellum; 2017. 16(2);607–11. DOI: 10.1007/s12311-016-0831-8

Chong HT, Tan CT. Review of multiple sclerosis with asian perspectives. Med J Malaysia; 2008. 63(5);356-61.

Available from:

Manfredonia F, Pasquali L, Dardano A, Iudice A, Murri L, Monzani F. Review of the clinical evidence for interferon beta 1a in the treatment of multiple sclerosis. Neuropsychiatric Disease and Treatment; 2008. 4(2);321-36. DOI: 10.2147/ndt.s476

Bermel RA, Rudick RA. Interferon-beta treatment for multiple sclerosis. Neurotherapeutics; 2007. 4(4);633-46. DOI: 0.1016/j.nurt.2007.07.001

Deisenhammer F, Schellekens H, Bertolotto A. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. J Neurol; 2004. 251(2);31-9. DOI: 10.1007/s00415-004-1206-5

Namaka M, Pollitt-Smith M, Gupta A, Klowak M, Vasconcelos M, Turcotte D, et al. The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis. Curr Med Res Opin; 2006. 22(2);223-39. DOI: 10.1185/030079906X80413

Torkildsen O, Myhr KM, Bo L. Disease Modifying Treatment for Multiple Sclerosis - A Review of Approved Medications. European Journal of Neurology; 2015. 23(1);18-27.

DOI: 10.1111/ene.12883

Kieseier BC. The mechanism of action of interferon- in relapsing multiple sclerosis. CNS Drugs; 2011. 25(6):491-502. DOI: 10.2165/11591110-000000000-00000.


  • There are currently no refbacks.